The long-acting Pi-agonlst salmeterol inhibits in vitro the release of inflammatory mediators up to 20 h. These mediators are involved in ultrasonically nebulized distilled water (UNDW)-induced bronchoconstriction. We investigated whether salmeterol provides prolonged protection against UNDW provocation and whether this effect was paralleled by its bronchodilator effects.
The long-acting p2-agonist salmeterol xinafoate has a higher potency and much longer duration of action than the short-acting p2-agonists such as salbutamol [1] . Unlike the short-acting j32-agonists, it has been suggest ed that salmeterol has some anti-inflammatory proper ties. In vitro data showed that salmeterol blocked mast cell mediator release 10-35 times more potently than salbutamol, with effects persisting for more than 20 h [2] , Salmeterol, but not salbutamol, also had inhibitory effects on other inflammatory cells such as eosinophils and alveolar macrophages [3] , and afforded long-last ing inhibition of increases in vascular permeability [4] . Despite these cellular and vascular effects, evidence that they are of clinical relevance is still lacking. No change in bronchial hyperresponsiveness (BHR) was reported after 6 weeks of treatment with salmeterol [5] and analysis of bronchoalveolar lavage (BAL) cell profile has not shown convincing evidence of an anti-inflammatory effect [6] .
On the other hand, Twentyman et al. [7] suggested that salmeterol has some additional effects, Le. preventing the increase in BHR after allergen provocation, beyond the tim e o f bronchodilation. Pedersen et a l [8] also re ported that salmeterol blocked the late asthmatic resp onse and increase in BHR after allergen provocation.
In contrast to pharmacological stimuli such as histam ine and methacholine, ultrasonically nebulized distilled water (UNDW) induces airway narrowing indirectly, by causing the release of endogenous mediators and possi bly by initiating vagal reflex mechanisms [9, 10] . Chal lenge with UNDW may increase BHR and induce a late asthmatic response, in the same manner as allergen expo sure [10] . Thus, the mechanism by which UNDW provo cation induces bronchoconstriction is likely to be similar to those involved in asthma provoked by naturally occur ring stimuli [9] . If the above-mentioned long-lasting cell-stabilizing effect of salmeterol were present in vivo, this drug might be expected to afford prolonged pro tection against UNDW provocation.
The present study was, therefore, designed to assess whether a single dose of salmeterol provided long-last ing protection against UNDW provocation and whether or not this was caused by its bronchodilating properties.
Materials and methods

Study design
This randomized, double-blind, placebo controlled, crossover trial consisted of two identical 3 day study periods, with a minimal interval of 1 week between the start of the two periods, in order to prevent any carry over effect. Subjects withheld rescue medication (salbu tamol 100 \xg by metered dose inhaler (MDI)) at least 6 h before each visit and rested for at least 15 min before starting measurements.
On the first day, at 22.00 h, baseline forced expiratory volume in one second (FEVi) was measured. Subsequent ly, study medication was administered, consisting of two inhalations of 25 |ag of salmeterol or placebo by MDI in random order. Flow-volume curves were recorded 20 and 40 min afterwards. On the second and third day, Le. 10 h (at 08.00 h), 20 h (at 18.00 h), and 34 h (08.00 h the next day) after inhalation of the study medication, FEVi measurements and a UNDW provocation were performed. Baseline FEVi on the starting evening of both periods had to be within 10%, otherwise the sec ond period was postponed to a later day.
Subjects
Nineteen nonsmoking asthmatic patients (6 males, 13 females) according to the criteria of the American Thoracic Society [11] , aged 16-54 (mean 28) yrs, entered the study. Sixteen persons were atopic, defined by an ele vated specific immunoglobulin E or positive intracutaneous tests against house dust mite or two of seven other tested common aero-allergens [12] . At study entry, FEVi had to be >50% predicted, and reversibility had to be >15% from prebronchodilator values in response to 200 |j.g salbutamol by MDI. The provocative concentration of histamine causing a 20% fall in FEVi (PC20,h) [13] had to be below 4 mg-mL' 1 for all subjects. None had any significant medical condition or an upper or lower respiratory tract infection within 6 weeks before the study. Seasonally allergic persons were not measured during the time when exposure to such allergen was like ly. During the study, the subjects used only salbutamol by MDI (100 jig) as needed to control symptoms. Anti inflammatory treatment (inhaled corticosteroids, nedo** cromil sodium, and cromolyn sodium) were withheld for at least 6 weeks preceding the study and systemic steroids for at least 6 months. Methylxanthines were stopped at least 48 h, anticholinergics and antihistam ines at least 24 h, before the start of the trial. The study was approved by the local hospital Ethics Committee; written informed consent was obtained from all partic ipants.
Methods
The bronchodilator response and reactions to UNDW provocation were assessed by FEVi, obtained from flowvolume curves recorded on a heated pneumotachograph (Spiro analyser ST 250®; Fukuda Sangyo Co., Tokyo). Baseline FEVi was recorded from the best of three repro ducible values (within 5%).
The UNDW provocation test was performed accord ing to the method described by Groot et a l [14] . An ultrasonic nebulizer (Ultraneb 99, DeVilbiss, Somerset, PA, USA) was used at a fixed output of 2.0Q±0.05 mL-min-1. The patient inhaled UNDW during tidal brea thing through a mouthpiece with tightened lips and the nose clipped. A Wright respirometer (British Oxygen Co., London, UK) was connected to a two-way valve (Laerdal IV, Stavanger, Norway), placed in-between the aerosol hose and the mouthpiece, to measure the total volume of inhaled air. After inhalation of 20 L of ambi ent air through the system, doubling volumes of air with UNDW (3,5,10, up to 160 L) were successively inhaled at 5 min intervals. The response to inhaled UNDW was assessed by FEVi after 90 and 180 s of each dose. The test was stopped if FEVi dropped by at least 20% or if 160 L of air with UNDW was inhaled. Before and after each test, the nebulizer chamber and aerosol hose were weighted. The cumulative dose of inhaled distilled water in mL H20 causing a 20% fall in FEVi from post-air values (PD20,UNDW), was calculated by linear interpo lation on a semilogarithmic curve.
Pretrial PC20,H was measured according to the method of Cockroft et al. [13] . In short, the patient inhaled doubling doses of histartiine phosphate from 0.03 to 16 mg-mL-1. The test was stopped if FEVi fell 20% from baseline, and a log dose-response curve was construct ed. The PC20,H was calculated in mg-mL' 1 by linear interpolation.
Sta tistical ana lysis
All PD20,UNDW data were logio transformed before analysis. FEVi data were expressed as % pred [15] . To calculate the treatment effect of salmeterol, differences between values (FEVi and PD20,UNDW) on salmeterol and on placebo were calculated and tested at each timepoint with the Wilcoxon signed rank test. The change in UNDW responsiveness (APD20,UNDW) was expressed in doubling doses (DD), calculated as:
((logPD20,UNDW -salmeterol)-(logPD20,UNDW -placebo))/log2
Period and carry-over effects were analysed accord ing to K och [16] . The coefficient of repeatability for PD20,UNDW was calculated for each subject using the two UNDW provocations in the placebo period (base line), at the same time of the day (08:00 h) according to the method of B la n d and A ltm a n [17] . Correlations between variables were performed with the Spearman correlation test. Regression lines were compared with analysis of variance (A N OVA) of repeated measure ments. For multiple comparisons, a Bonferroni correc tion was used. A p-value of 0.05 or less was considered significant for one test. For multiple comparisons, this boundary was set at 0.01. Data are reported as mean values (sem).
Results
Baseline FEVl and changes during study medication
Patient characteristics are listed in table 1. Seven teen patients completed the study. Two persons (sub jects No. 2 and 8) failed to return to the laboratory for lung function and provocation tests for the second treatment period (both after placebo in period one) and were withdrawn from the study. There were no period or carry-over effects between the two study periods at any time-point with regard to FEVl and PD20,undw data.
Baseline FEVl at 22.00 h on the starting day of both periods was similar with a variation of 1.8% (range 0.3-9.7% pred).
Salmeterol caused a significant and substantial degree of bronchodilatation versus placebo from 20 min up to 20 h after inhalation (per cent increase from baseline after salmeterol 14.8 (2.1), 17.7 (2.3), 13.9 (3.2) and 12.7 (1.7) 1% after 20 and 40 min and 10 and 20 h, respectively; all time-points significantly different from placebo (pcO.OOl), except for 34 h (p=0.55)) (table 2). The early morning dip seen after treatment with pla cebo (at 08.00 h) (mean change in FEVl -7,2%, range -28 to +5, compared to 22.00 h) was completely abol ished in all but one patient (p<0.001). The next morn ing (34 h after inhalation), salmeterol no longer provided protection against a morning dip.
UNDW provocation tests
Two of the 17 persons differed in their response to UNDW provocation from the others. Subject No, 1 appeared to be unresponsive to UNDW provocation. He recovered very fast from the constrictor effects of UNDW and showed a plateau in reaction of FEVl at 80% of the post-air values. Subject No. 10 turned out to be refrac tory to subsequent UNDW provocation tests. PD20,UNDW increased at subsequent tests, and he ended totally unre sponsive at the third test (table 3) . For these two patients, no real treatment effect of salmeterol could be calcu lated, but exclusion of their data did not alter the lev els of significance for the major outcome variables. The other 15 subjects demonstrated a good short-term repro ducibility of PD20,undw. The standard deviation of the differences for baseline UNDW provocations was 0.67 DD.
In the whole group (n=17), treatment with salmeterol resulted in protection against UNDW-induced bronchoconstriction for at least 20 h (table 3) . Ten hours after the inhalation of salmeterol, a significant increase was observed in the PD20,UNDW of 16.7 (2.3) mL H20 as compared with 3.3 (1.4) mL H20 after placebo (treat ment effect of 2.82 (0.35) DD, p<0.0001). In nine of the 17 subjects, the maximum dose of UNDW was reached. In these patients, the total amount of mL H20 inhaled at that time was taken for analysis, since no PD20,UNDW could be reached after salmeterol. Twenty hours after inhalation (at 18.00 h) there was still a significant pro tection for UNDW, with a PD20,UNDW of 7.0 (1.5) mL H20 after salmeterol as compared with 3.3 (0.7) mL H20 after placebo (treatment effect of 1.09 (0.23) DD, p=0.0008). After 34 h (at 08.00 h) PD20}UNDW values returned to placebo level (4.8 (1.6) mLH20 after salme terol as compared with 5.0 (2.0) mL H20 after placebo (treatment effect of 0.1 (0,2) DD, p=0.55)).
Relationship between UNDW provocation and airway calibre
For each time-point, APD20,UNDW was not correlat ed with the corresponding change in FEVl (AFEVi) from placebo to salmeterol (all rc0.ll, p>0.65). The slopes of the regression lines through these points after 10 and 20, but not after 34 h on salmeterol and placebo differed significantly from zero (p~0.001 and p=0.03, respectively), indicating a (linear) relationship between starting airway calibre and BHR. The slopes between the regression lines of salmeterol in compari son with placebo were not different at any time-point (all p>0.49), but again, both after 10 and 20 h, the treat ment effect of salmeterol was highly significant, plac ing the lines after salmeterol parallel at a higher level compared to placebo (p=0.000 and p=0.002, respec tively), Previously, it has been shown that there is a lin ear relationship between FEVl and the provocative concentration of methacholine causing a 20% fall in FEVl (PC20,m) [18] . Under the assumption of a simi lar relationship between FEVl and PD20,UNDW and because the measurements on salmeterol and on place bo are paired, the relationship between PD20,UNDW, and FEVl can be describe statistically with one equation for the regression lines at each time-point: the treatment effect is +2.15 DD and the effect through FEVl is 0.035x18.4=0.65, hence 2.8 DD as found in the study. After 20 h, the treatment effect is +0.82 and the effect through FEVl is 0.028x10.4=0.29 (hence the real found protection of 1.1 DD). This means that only 23% (0.65/2.80x100%) of the afforded protection can be explained by bronchodilation, and 77% by a direct effect of salmeterol. After 20 h these values are 26 and 74%, respectively.
Discussion
This study shows that a single dose of salmeterol aff ords both bronchodilation and protection against UNDW provocation up to 20 h in asthmatic patients who did not use anti-inflammatory medication. Protection against UNDW provocation beyond the period of bronchodila tion did not occur. In 11 of 17 patients, the inhibition of bronchoconstriction to UNDW decreased significantly between 10 and 20 h, at which time bronchodilation persisted. However, protection was still more than 1 DD after 20 h, and up to this time, only a maximum of 26% of the protection could be explained by the bronchodilating effect of salmeterol.
The duration of protection against UNDW challenge was in line with the in vitro activity of salmeterol. UNDW provocation is thought to be mediated by the release of mast cell mediators [9, 10] . Salmeterol inhibits the release of these mediators from sensitized human lung fragments for more than 20 h [2] . In the present study, a single dose of salmeterol afforded protection at 10 h of almost 3 DD, and, although the magnitude of the protection weaned, protection was still more than 1 DD after 20 h. In this way, salmeterol showed, in vivo, a relevant protection during the period of blocking medi ators in vitro [2] .
In accordance with B o o t h et al [19] , no increase in BHR after withdrawal of salmeterol was found in our study. Thirty four hours after inhalation of salmeterol (more than three times the half-life), no rebound BHR to UNDW occurred, the P D 20,UNDW being 0.12 DD above placebo.
Salmeterol also induced bronchodilation for more than 20 h, and protected against the early morning dip 10 h after inhalation. T w en ty m a n et al [7] tested bron chodilation of a single dose of salmeterol up to 34 h, but regular measurements were discontinued after 9.5 h. When starting measurements again after 32 h, sal meterol no longer afforded bronchodilation. In a group of asthmatic patients with similar characteristics as in the present study, R abe et al [20] showed that salmeterol decreased airway tone significantly over a whole 24 h period, compared with placebo. Because of multi ple comparisons, however, the bronchodilating effect was not significant beyond 12 h at the individual timepoints. Our study clearly shows a bronchodilation up to 20 h, which disappeared after 34 h.
Besides bronchodilation, an important property of salmeterol could be the ability to afford protection of airways smooth muscle against bronchoconstrictor med iators with time-course characteristics different from those observed for bronchodilation [7] . Since baseline airway function correlates somewhat with airway reac tivity [18] , the inhibitory effect of a bronchodilator could be due to a change in airway calibre. In this study, both bronchodilation and protection lasted more than 20 h but less than 34 h. More measurements of UNDW provo cation during this period would be needed to determine exactly the duration of action and to distinguish bet ween protection and bronchodilation. However, we made measurements at 10 h intervals to avoid confounding problems such as a temporary (small) increase in BHR after UNDW provocation [10, 21] , and to avoid refrac toriness after repeated UNDW measurements [14, 21] , which may persist up to 4 h after the last challenge [22, 23] . Despite this, two patients (subjects No. 2 (dropped out) and 10) became refractory to successive UNDW provocations.
No correlation was found between bronchodilation (A F E V i) and protection (APD20,UNDW) provided by sal meterol at any time-point, indicating that protection was not caused by bronchodilation. However, the number of patients in our study is probably too small to state that there might not be a correlation with a much larger population. On the other hand, figure 1 shows that in individual patients the protection afforded by salmeterol is independent of airway calibre, and there were moderate-to-severe responses to inhalation to water at a time when airway calibre was optimal. The regression lines through these points again show a highly signifi cant treatment effect of salmeterol, by shifting the lines at 10 and 20 h parallel to higher levels than after place bo. From the equations of the regression lines on sal meterol and on placebo at the various time-points, it can be calculated that up to 20 h, only a maximum of 26% of the protection can be explained by the bronchodilating effect of salmeterol. Therefore, there seems to be a differential effect of salmeterol on lung function and the response to UNDW, A similar dissociation has been shown with sodium cromoglycate, which had no effect on lung function, but did block UNDW provocation [24] . Conversely, ipratropium bromide in doses up to 160 jLxg caused bronchodilation, but did not change the response to challenge with UNDW [25] .
Other mechanisms are thus likely to be involved in the protective effects of salmeterol against UNDW-induced bronchoconstriction. The term functional antago nism is often used to describe the protective effects of P2-agonists during provocation tests. P2-agonists maY prevent smooth muscle contraction, irrespective of the constrictor mediator, by acting on a different receptor on the same cell, which opposes this constriction [26] . In this way, pharmacological effects of p2-agonists are different between smooth muscle relaxation and pro tection against bronchoconstriction [27] . It has previ ously been shown that p2-agonists provide true functional antagonistic protection at the level of the smooth mus cle against direct pharmacological stimuli as histamine and methacholine [28] . UNDW, however, is thought not to act directly at the level of the smooth muscle, but to induce airway narrowing indirectly [9, 10] . Therefore, mechanisms other than bronchodilation and functional antagonism should be considered to explain this appar ent dissociation.
O 'Connor et al [29] showed that P2-agonists have an additional inhibitory nonsmooth muscle effect on bronchoconstrictor stimuli that involve mast cell activation, in affording a greater protection against adenosine mono phosphate-than methacholine-induced bronchoconstri ction. Salmeterol has several acute anti-inflammatory effects in vitro that may contribute, e.g. the strong inhi bition of the release of mast cell mediators [2] , involved in the mechanism of action of UNDW. Thus, although the evidence is only indirect, this protection may indi cate long-lasting cell-stabilizing effects of salmeterol in vivo up to 20 h rather than functional antagonism.
Finally, in a number of patients, the protection of sal meterol against UNDW decreased, while bronchodila tion persisted. This dichotomy between duration of bronchodilation and protection against a bronchoconstrictor stimulus has already been described by A hrens et al [30] . These differences in time course could reflect differences in the mechanism for these two p2-agonistic actions. However, an alternative explanation could be the differences in potency of the bronchoconstrictor stimulus. A larger concentration of a p2-agonist may be required to prevent contraction to a potent stimulus as a provocation test, as compared with the concentration of the drug to produce relaxation of the relatively mod est level of bronchospasm at baseline [31] . Several stud ies showed a relationship between bronchodilator dose and the degree of inhibition of provocation [32] . A greater concentration of salmeterol may be required to prevent contraction to UNDW provocation than is required to produce relaxation. However, the concentration of salmeterol required to prevent mast cell mediator release may similarly be higher than the concentration required to prevent contraction of the muscle by the mediators released.
Whether this nonbronchodilator effect of salmeterol also provides clinically relevant effects or persists after prolonged therapy, is at present unclear. No change in BHR was reported after 6 weeks of treatment with sal meterol [7] . On the other hand, salmeterol significantly improved the treatment of (chronic) bronchial asthma and resulted in a clinical significant improvement in qual ity of life versus placebo and salbutamol [33], G r e e n in g et a l [34] showed that adding salmeterol to inhaled cor ticosteroid therapy was more appropriate for patients with inadequately controlled asthma on low-dose inhaled corticosteroids than doubling this dose. Finally, in this study, salmeterol afforded a significant protection of more thaii 20 h against a naturally occurring stimulus, which may be very relevant for asthma management.
In conclusion, our study shows that a single dose of salmeterol in mild-to-moderate asthma causes bron chodilation and protection independently of this bron chodilation against a physiological bronchoconstrictor stimulus for more than 20 h.
